AdisInsight profiles relating to the Zika virus are now available to access for free, as part of Springer Nature’s pledge to share data that can support public health emergencies.
Springer Nature is part of a group of leading global health bodies including academic journals, NGOs, research funders and institutes that published a joint statement earlier this year, committing to share data and results relevant to the current Zika crisis and future public health emergencies.
In line with this, Springer Nature is opening up its resources related to the Zika virus to help students, researchers, health care professionals, and other scientifically minded individuals to better understand the multidisciplinary approach to containing the virus and caring for patients.
We’ve included open-access links to drug profiles and clinical trial profiles from AdisInsight relevant to the Zika virus:
Drug profiles:
- Astrodrimer
- BCX 4430
- GLS 5700
- HSRx 431
- Interferon-alpha-n3
- Ranpirnase
- Research programme: antiviral therapeutics – Ennaid Therapeutics
- Research programme: antiviral therapeutics – Takeda
- Research programme: anti-infective mRNA therapeutics – Valera
- Research programme: anti-viral therapeutics – US Phytotherapy
- Research programme: antiviral vaccines – Vaxart
- Research programme: infectious disease vaccines – NewLink Genetics
- Research programme: infectious disease vaccines – PaxVax
- Research programme: mosquito-borne diseases vaccine – SEEK
- Research programme: nanoparticle viral therapies – NanoViricides
- Research programme: recombinat protein subunit vaccines – Hawaii Biotech
- Research programme: RNA virus vaccines – Sementis/University of South Australia
- Research programme: vaccines – Bharat Biotech
- Research programme: viral budding inhibitors – Biotron
- Research programme: viral vaccines – Mymetics
- Research programme: viral vaccines – Pharos Biologicals
- Research programme: viral vaccines – Valneva
- Research programme: virus-like particle vaccines – VBI Vaccines
- Research programme: Zika virus infection vaccine – CaroGen Corporation
- Research programme: Zika virus vaccine – Emergent BioSolutions
- Research programme: Zika virus vaccine – GeoVax Labs
- Research programme: Zika virus vaccine – GlaxoSmithKline/NIH
- Research programme: Zika virus vaccine – Immunovaccine
- Research programme: Zika virus vaccine – Oxis International
- Research programme: Zika virus vaccine – Sanofi Pasteur
- Rintatolimod
- STP 602
- Zika and dengue combined vaccine- Excivion/Xenetic Biosciences
- Zika virus vaccine – Protein Sciences Corporation/Sinergium Biotech
Trial profiles:
- A phase I trial of mRNA Zika virus vaccine
- A phase I trial of Zika virus vaccine
- A study of HSRx431 for the treatment of Zika virus
- Phase I, Placebo-Controlled, Double-Blind Study To Evaluate The Safety, Tolerability, AND Immunogenicity Of GLS-5700, Administered ID Followed By Electroporation In Dengue Virus-Seropositive Adults
- Phase I study of Zika vaccine in patients with Zika infection
- Phase I study of Zika purified inactivated virus vaccine
- Phase I trial of Zika vaccine in patients with Zika-virus-infection
Additional research has been organized into various disciplines and made freely available – this includes articles, commentaries, blog posts and news items. To view all of the content available, please visit the landing page.
If you are interested in learning more about AdisInsight, please complete your details in the form and one of our colleagues will be in touch
